September 23, 2014

Sandoz announced the launch of Kerydin (tavaborole) topical solution, 5% in the United States. Kerydin is the first oxaborole antifungal for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes, the company stated. 

September 2, 2014

Sandoz last week announced the U.S. market introduction of decitabine for injection, a generic version of Eisai’s Dacogen.

July 28, 2014

The Food and Drug Administration has accepted a license application by Sandoz, Novartis' generics company, for a potential generic biologic drug, the company announced Monday.

July 21, 2014

Sandoz on Monday announced an agreement with Anacor Pharmaceuticals to obtain exclusive rights to commercialize Kerydin (tavaborole) topical solution, 5%, through its branded dermatology business, PharmaDerm.

July 14, 2014

Sandoz on Monday announced the introduction of tobramycin inhalation solution, USP into the U.S. market. The drug is an authorized generic version of Tobi from Novartis.

July 7, 2014

Sandoz announced the launch of valsartan tablets, an authorized generic version of Diovan tablets which is used for the treatment of high blood pressure.

June 18, 2014

Canada’s Federal Court ruled recently that the country’s Patented Medicine Prices Review Board — a federal tribunal that regulates pricing on branded medicines — could not extend price-control measures to cover generic drug companies, according to published reports.

June 10, 2014

Canada’s Federal court ruled recently that the country’s Patented Medicine Prices Review Board – a federal tribunal that regulates pricing on branded medicines – could not extend price control measures to cover generic drug companies.

June 3, 2014

Sandoz on Tuesday announced an agreement with Upsher-Smith to obtain exclusive U.S. distribution rights for its branded potassium chloride line of products, Klor-Con, and market them under the Sandoz name.

May 15, 2014

Teva Pharmaceutical was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis, drug 10 days before the patent on the medication expires, according to a Bloomberg report published Thursday morning.

April 28, 2014

Sandoz on Monday announced the introduction of its adapalene 0.3% gel, a generic version of Differin gel, 0.3% from Galderma Labs.

April 22, 2014

Impax Labs on Monday announced the its board of directors appointed G. Frederick Wilson as the company's president and CEO, effective April 29.

April 2, 2014

Sandoz on Tuesday announced the U.S. market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex Ointment.

March 28, 2014

Sandoz announced the U.S. launch of lansoprazole capsules amoxicillin capsules, USP, and clarithromycin tablets, USP, the generic version of Prevpac.

February 6, 2014

Sandoz announced the launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol.

January 30, 2014

Novartis Consumer Health will be relaunching Theraflu for the 2014-2015 cough-cold season, Brian McNamara, Novartis division head OTC, told analysts.

January 14, 2014

Drug maker Sandoz has started a late-stage clinical trial of a biotech drug used to treat autoimmune disorders, the company said.

December 2, 2013

Sandoz will market an authorized generic version of an attention deficit hyperactivity disorder drug made by Shire under a contract between the two companies, Shire said Monday.

November 22, 2013

Sandoz has launched an authorized generic version of a topical drug for treating actinic keratosis, the company said.

September 23, 2013

Sandoz has launched an authorized generic drug for treating a disease commonly known as pre-leukemia, the company said on Monday.

August 20, 2013

Generic drug maker Sandoz has relaunched a website to promote its biosimilars business.

July 26, 2013

A federal court has ruled in favor of generic drug maker Sandoz in a case involving a drug for multiple sclerosis, Sandoz said.

July 22, 2013

An announcement Monday by generic drug maker Sandoz gives a glimpse of what could happen in the United States when biosimilars start to become available.

July 2, 2013

Sandoz, the generics division of Swiss drug maker Novartis, announced the launch of metronidazole 1% topical gel, calling it the first generic version of Galderma Labs' Metrogel.